Stifel raised the firm’s price target on Deciphera to $22 from $20 and keeps a Buy rating on the shares. Vimseltinib’s pivotal data “look approvable” in the U.S. and support a view that the drug can achieve higher sales potential than Turalio on a differentiated label, says the analyst. Following the data, the firm has increased confidence in a vimseltinib U.S. approval with a differentiated label that will allow a second-to-market drug to “win and expand the TGCT market,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCPH:
- Deciphera price target raised to $30 from $25 at H.C. Wainwright
- Deciphera upgraded to Buy from Hold at JonesResearch
- Piper upgrades Deciphera, sees vimseltinib and Qinlock poised for upside
- Deciphera upgraded to Overweight from Neutral at Piper Sandler
- Deciphera: MOTION study of vimseltinib met primary endpoint, key 2ndry endpoints
